机构:[1]Guangdong Metabolic Disease Research Center of Integrated Chineseand Western Medicine, Guangdong, China[2]Key Laboratory of GlucolipidMetabolic Disorder, Ministry of Education of China, Guangdong, China[3]KeyUnit of Modulating Liver to Treat Hyperlipemia SATCM (State Administrationof Traditional Chinese Medicine), Guangdong, China[4]Institute of Chinese Medicinal Sciences, Guangdong TCM Key Laboratory Against Metabolic Diseases, Guangdong Pharmaceutical University, Guangdong, China[5]Departmentof Cardiovascular Diseases, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong, China
This study was
supported by grants from the National Natural Science Funds, China ( No.
81530102) and the construction of the international cooperation base of
Guangdong Provincial Science and Technology Department; the construction
of the international cooperation base for the prevention and treatment of
metabolic diseases (2016B050501003), Guangdong Provincial TCM Administration
Department Grant (20151269), Basic and Applied Basic Research fund
of Guangdong Province (2021A1515012553), Innovative Strong School Project
of Guangdong Pharmaceutical University (2018KQNCX130), Basic and Applied
Basic Research fund of Guangdong Province (2019A1515110123), The Medical
Science and Technology Research Fund of Guangdong Province (A2019531).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|3 区医学
小类|2 区全科医学与补充医学3 区药学
最新[2025]版:
大类|2 区医学
小类|2 区全科医学与补充医学2 区药学
第一作者:
第一作者机构:[1]Guangdong Metabolic Disease Research Center of Integrated Chineseand Western Medicine, Guangdong, China[2]Key Laboratory of GlucolipidMetabolic Disorder, Ministry of Education of China, Guangdong, China
共同第一作者:
通讯作者:
通讯机构:[1]Guangdong Metabolic Disease Research Center of Integrated Chineseand Western Medicine, Guangdong, China[2]Key Laboratory of GlucolipidMetabolic Disorder, Ministry of Education of China, Guangdong, China[3]KeyUnit of Modulating Liver to Treat Hyperlipemia SATCM (State Administrationof Traditional Chinese Medicine), Guangdong, China[4]Institute of Chinese Medicinal Sciences, Guangdong TCM Key Laboratory Against Metabolic Diseases, Guangdong Pharmaceutical University, Guangdong, China
推荐引用方式(GB/T 7714):
Song Lixia,Wang Ke,Yin Jianying,et al.Traditional Chinese Medicine Fufang-Zhenzhu-Tiaozhi capsule prevents renal injury in diabetic minipigs with coronary heart disease[J].Chinese medicine.2022,17(1):102.doi:10.1186/s13020-022-00648-x.
APA:
Song Lixia,Wang Ke,Yin Jianying,Yang Yiqi,Li Bo...&Guo Jiao.(2022).Traditional Chinese Medicine Fufang-Zhenzhu-Tiaozhi capsule prevents renal injury in diabetic minipigs with coronary heart disease.Chinese medicine,17,(1)
MLA:
Song Lixia,et al."Traditional Chinese Medicine Fufang-Zhenzhu-Tiaozhi capsule prevents renal injury in diabetic minipigs with coronary heart disease".Chinese medicine 17..1(2022):102